Twitter Q&A on drug development next Thursday

By Suzie Siegel

While abeyance for “the cure,” many of us would settle by reason of more effective drugs that have fewer espouse a cause effects. Let’s talk about this at 9 p.m. (EST) Thursday, Sept. 24, without ceasing Twitter.

Dr. Laurence Baker

Sarcoma medical oncologist Laurence H. Baker, DO, desire answer your questions during the 45-sixtieth part of an hour chat. Use the hashtag #scmsm to tweet and contribute other people’s tweets.

Here are the basics without ceasing Twitter: Before the prattle, you may want to learn respecting drug development here: http://www.cancer.clear/research-and-advocacy/introduction-cancerresearch/drug-discovery-and-development.

Dr. Baker, a professor of inward medicine and pharmacology at the University of Michigan Medical School in Ann Arbor, brings a money of knowledge to the subject. He has served for example director for clinical research and hematology/oncology at UM’s Comprehensive Cancer Center; presiding officer of the Southwest Oncology Group, the largest clinical trials making in the United States; executive guide of the Sarcoma Alliance for Research through Collaboration, a public cooperative group that runs sarcoma clinical trials; and president of the Connective Tissue Oncology Society, ~y international group of sarcoma physicians and scientists.

Corrie Painter, PhD

He has treated sarcoma patients by reason of more than 40 years, but instead of retiring, he helped establish UM’s sarcoma survivorship clinic finally year.  He tweets @laurencebaker2. My Twitter co-hosts behest be Bert E. Thomas IV, PhD, MBA, @SFA_Bert and Corrie Painter, PhD, @Corrie_Painter. Bert is CEO of the Sarcoma Foundation of America, the Alliance’s sister organized being in Damascus, MD.  Corrie, one angiosarcoma survivor, is vice president of Angiosarcoma Awareness and combine director of operations and scientific outreach at the Broad Institute of MIT and Harvard in Boston.  I’m a leiomyosarcoma survivor who served put ~ the Sarcoma Alliance board 2008-2013. I tweet @SuzieSiegel. The Alliance supports this confabulation.

I’ll update this post in the same proportion that more people commit to the confabulate. 

This year has brought exciting news on trabectedin (Yondelis), eribulin (Halaven), aldoxorubicin and evofosfamide (TH-302). Some of you may have ~ing following the news on other ascertained drugs, wondering why it takes to such a degree long for them to get FDA approval. Other feasible questions include:
      — How lingering does it take and how abundant does it cost to develop modern drugs?
      — Why does it take longer toward some drugs to be approved in the U.S.? Yondelis, for example, is already approved in divers countries. 
      — What are the challenges of developing drugs for rare cancers like sarcoma?
      — Are in that place initiatives to speed up the transaction without sacrificing safety? 
      — In adding to raising money for research, for what reason can people help speed up the projection?

What would you like to beg?

Monday-Friday, you will receive individual awesome nonprofit video in your in-box.

Both comments and pings are currently closed.